Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Jul 4;19(9):1824–1834.e2. doi: 10.1016/j.cgh.2020.06.068

Table 2.

Multivariable adjusted case control odds ratios with 95% confidence limits and model fit and prediction statistics for cases defined by AGREE consensus definition for the predictive models built with factors available prior to diagnostic endoscopy, factors available at diagnostic endoscopy, and factors available after histology results.

Factors available prior to diagnostic endoscopy Factors available at diagnostic endoscopy Factors available after histology results excluding eosinophil count Factors available after histology results including eosinophil count

Age at biopsy (per year) 0.94 (0.93 – 0.96) 0.96 (0.94 – 0.97) 0.96 (0.94 – 0.98) 0.97 (0.94 – 1.00)
Male sex versus female 2.86 (1.80 – 4.55) 2.20 (1.29 – 3.76) 2.99 (1.56 – 5.72)
White race versus others 3.51 (1.76 – 7.04)
History of atopic condition or food allergy versus neither 1.72 (1.08 – 2.75)
Dysphagia at baseline 15.01 (6.12 – 36.83) 7.58 (2.7 – 21.27) 6.14 (2.03 – 18.53) 12.27 (1.37 – 110.01)
Rings, furrows, edema, white plaques, narrowing, or crepe paper appearance on endoscopy 20.69 (11.95 – 35.82) 9.74 (5.33 – 17.77) 5.55 (2.15 – 14.38)
Erosive esophagitis on endoscopy 0.28 (0.1 – 0.74) 0.36 (0.14 – 0.92)
Hiatus hernia on endoscopy 0.53 (0.29 – 0.97)
Eosinophil degranulation 3.80 (1.94 – 7.46)
Eosinophil microabscess 9.05 (3.08 – 26.55)
Overall peak eosinophil count (per additional ten eosinophils per HPF) 1.54 (1.12 – 1.22)

Model Akaike information criterion* 517.19 372.39 312.44 140.64
Area under the receiver-operator characteristic curve 0.84 (0.81 – 0.88) 0.92 (0.89 – 0.94) 0.95 (0.93 – 0.97) 0.99 (0.99 – 1.00)
Cross-validated area under the receiver-operator characteristic curve 0.84 (0.80 – 0.87) 0.91 (0.88 – 0.94) 0.94 (0.92 – 0.96) 0.99 (0.98 – 1.00)
*

Akaike information criterion measures model fit, with a lower value indicating a better fit. AGREE, a working group on proton-pump inhibitor responsive esophageal eosinophilia, HPF, high power field.